Drug-induced osteoporosis

Summary

Drug-induced osteoporosis (MONDO:0024650) is a disease. A subtype of osteoporosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	drug-induced osteoporosis
Mondo ID	MONDO:0024650
ICD-11	691296096
SNOMED CT	14651005
UMLS	C0264115
MedGen	538336
GARD	0025446
Is cancer (heuristic)	no

Also known as: drug-induced osteoporosis

Disease family

This is a subtype of osteoporosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › bone disorder › bone remodeling disease › bone resorption disease › osteoporosis › drug-induced osteoporosis

Related subtypes (6): nephrolithiasis/osteoporosis, hypophosphatemic, postmenopausal osteoporosis, X-linked osteoporosis with fractures, idiopathic juvenile osteoporosis, pregnancy associated osteoporosis, premenopausal osteoporosis

Subtypes (1): corticosteroid-induced osteoporosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.